title: The advanced glycation endproduct pentosidine and monocyte activation in uremia.
abstract: BACKGROUND
  Advanced glycation endproducts (AGEs) contribute to the pathogenesis of vascular complications in diabetes, aging and end-stage renal disease (ESRD). Immune abnormalities in patients with chronic renal failure and those treated by dialysis contribute to high rates of morbidity and mortality. We therefore sought a relationship between a circulating marker of immune dysfunction and plasma levels of the AGE pentosidine.
  
  
  METHODS
  We studied non-diabetic patients with mild to advanced renal failure (n = 60), and with ESRD treated by hemodialysis (HD) (n = 44) and peritoneal dialysis (PD) (n = 19). The plasma protein content of the well characterized AGE, pentosidine was measured using HPLC. In the same samples the monocyte activation product neopterin was measured by RIA.
  
  
  RESULTS
  Plasma levels of pentosidine and neopterin increased in parallel with the progression of renal failure. Pentosidine and neopterin were highly correlated in all patients even after adjustment for Ccr. This correlation was also present in patients with ESRD.
  
  
  CONCLUSIONS
  These data suggest that the AGE pentosidine is associated with monocyte activation in renal failure, an interaction which may contribute to accelerated rates of complication and death by as yet unknown mechanisms.
authors.affiliation: Department of Medicine, Case-Western Reserve University, Cleveland, Ohio, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Friedlander
authors.forename: V
authors.initials: V
authors.lastname: Witko-Sarsat
authors.forename: A T
authors.initials: AT
authors.lastname: Nguyen
authors.forename: Y C
authors.initials: YC
authors.lastname: Wu
authors.forename: M
authors.initials: M
authors.lastname: Labrunte
authors.forename: C
authors.initials: C
authors.lastname: Verger
authors.forename: P
authors.initials: P
authors.lastname: Jungers
authors.forename: B
authors.initials: B
authors.lastname: Descamps-Latscha
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001708:Biopterins / Q000031:analogs & derivatives* / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D003432:Cross-Linking Reagents / Q000378:metabolism; D018450:Disease Progression; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D009000:Monocytes / Q000276:immunology*; D019798:Neopterin; D010530:Peritoneal Dialysis; D011863:Radioimmunoassay; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000628:therapy
chemical_list: D015415:Biomarkers; D003432:Cross-Linking Reagents; D017127:Glycation End Products, Advanced; D001708:Biopterins; D019798:Neopterin; D001120:Arginine; C062187:pentosidine; D008239:Lysine